Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

Johnson & Johnson (JNJ) raised its full-year sales outlook after Q3 2026 operational revenue grew 6%, putting the company on track to top $100 billion in annual revenue for the first time.

Pharmaceuticals drove the quarter, with cancer treatments leading demand. The medical device segment lagged, growing just 2.5%. Two pressures held it back: Middle East disruptions and China's bulk-buying program. Interpretation: the gap between 6% company-wide growth and 2.5% in devices shows how much pharma is carrying the results.

Management plans to restore device momentum through new product launches. It is also leaning toward spinning off its DePuy Synthes orthopedics subsidiary by mid-2027. Interpretation: a separation would sharpen JNJ's mix toward the faster-growing pharma business, though the source provides no valuation or terms for any deal.

The raised guidance and the $100 billion milestone give the long-term bull case a concrete scorecard. The device shortfall is the open question, since the rebound depends on launches that have yet to prove themselves against China and Middle East headwinds.

PFE, the other name in the pharmaceutical group, offers a natural comparison point for how large-cap drugmakers are being valued against JNJ's pharma-led growth.